» Articles » PMID: 38705936

CT Findings As Predictive Factors for Treatment Failure in Mycobacterium Abscessus Complex Lung Disease: a Retrospective Cohort Study

Overview
Journal Jpn J Radiol
Publisher Springer
Specialty Radiology
Date 2024 May 5
PMID 38705936
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Mycobacterium abscessus complex (MABC) commonly causes lung disease (LD) and has a high treatment failure rate of around 50%. In this study, our objective is to investigate specific CT patterns for predicting treatment prognosis and monitoring treatment response, thus providing valuable insights for clinical physicians in the management of MABC-LD treatment.

Methods: We retrospectively assessed 34 patients with MABC-LD treated between January 2015 and December 2020. CT scores for bronchiectasis, cellular bronchiolitis, consolidation, cavities, and nodules were measured at initiation and after treatment. The ability of the CT scores to predict treatment outcomes was analyzed in logistic regression analyses.

Results: The CT scoring system had excellent inter-reader agreement (all intraclass correlation coefficients, > 0.82). The treatment failure (TF) group (17/34; 50%) had higher cavitation diameter (p = 0.049) and extension (p = 0.041) at initial CT and higher cavitation diameter (p = 0.049) and extension (p =0 .045), consolidation (p = 0.022), and total (p = 0.013) scores at follow-up CT than the treatment success (TS) group. The changes of total score and consolidation score (p = 0.049 and 0.024, respectively) increased in the TF group more than the TS group between the initial and follow-up CT. Multivariable logistic regression analysis showed initial cavitation extension, follow-up consolidation extension, and change in consolidation extension (adjusted odds ratio: 2.512, 2.495, and 9.094, respectively, per 1-point increase; all p < 0.05) were significant predictors of treatment failure.

Conclusions: A high pre-treatment cavitation extension score and an increase in the consolidation extension score during treatment on CT could be alarm signs of treatment failure requiring tailor the treatment of MABC-LD carefully.

Citing Articles

Toward better cures for lung disease.

Dartois V, Dick T Clin Microbiol Rev. 2024; 37(4):e0008023.

PMID: 39360834 PMC: 11629636. DOI: 10.1128/cmr.00080-23.

References
1.
Daley C, Iaccarino J, Lange C, Cambau E, Wallace Jr R, Andrejak C . Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. Clin Infect Dis. 2020; 71(4):e1-e36. PMC: 7768748. DOI: 10.1093/cid/ciaa241. View

2.
Lai C, Tan C, Chou C, Hsu H, Liao C, Huang Y . Increasing incidence of nontuberculous mycobacteria, Taiwan, 2000-2008. Emerg Infect Dis. 2010; 16(2):294-6. PMC: 2958002. DOI: 10.3201/eid1602.090675. View

3.
Winthrop K, Marras T, Adjemian J, Zhang H, Wang P, Zhang Q . Incidence and Prevalence of Nontuberculous Mycobacterial Lung Disease in a Large U.S. Managed Care Health Plan, 2008-2015. Ann Am Thorac Soc. 2019; 17(2):178-185. PMC: 6993793. DOI: 10.1513/AnnalsATS.201804-236OC. View

4.
Haworth C, Banks J, Capstick T, Fisher A, Gorsuch T, Laurenson I . British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax. 2017; 72(Suppl 2):ii1-ii64. DOI: 10.1136/thoraxjnl-2017-210927. View

5.
Johansen M, Herrmann J, Kremer L . Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus. Nat Rev Microbiol. 2020; 18(7):392-407. DOI: 10.1038/s41579-020-0331-1. View